New Medium Enhances Hybridoma Protein and Monoclonal Antibody Production

Mediatech Inc have announced the introduction of hybriGRO SF™, which enhances the performance of monoclonal antibody-producing hybridoma cells.

Monoclonal antibodies (mAbs) derived from hybridoma cells (cells formed from the fusion of antibody-producing B-cells with myeloma cells) are used extensively in the prevention, diagnosis, and treatment of cancers and other diseases.

hybriGRO SF™ is an advanced serum-free (SF) and animal-derived component-free (ADCF) defined medium which provides the consistency demanded of a defined media in commercial mAb production.

“The use of serum- and animal-origin free defined media is critical in the culture of hybridoma cells for the production of monoclonal antibodies. Our data shows that hybriGRO SF provides a significant increase in cell viability and protein production over existing defined media, with strong protein-product stability in long-term culture,” said Jason Walsh, Business Director of Mediatech. “The release of hybriGRO SF is a key addition to the Corning cellgro® free portfolio, supporting the needs of life scientists ranging from basic research to biopharmaceutical production.”